Theravance’s Telavancin Prompts Renal Concerns, But No Questions From FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Safety signal from trials appears in FDA’s briefing materials, but not in list of questions for the Anti-Infective Drugs Advisory Committee.